Current situation and Future of Veterinary Medicines and Related Industries in Japan and the US – New Technologies that Change Future –

The captioned article has been written by Dr. Yuki Ujimasa, DVM, MS, President of AHRMS, Inc., and published on the Journal of the Japan Veterinary Medical Association since October 2019. It recently became public via the following link:
http://nichiju.lin.gr.jp/mag/07210/a4.pdf
Sorry to say, it is described only in Japanese. The chapters of the article are as follows:
1. Recent activities by multi-national animal health pharmaceutical companies and domestic companies
2. New technologies that can change husbandry industries
3. Impact of emerging and re-emerging infectious diseases in food animals and Possibilities of plant-based meat and cultured meat
4. Telemedicine in veterinary medicines
5. Changes of distribution system and home-delivery in companion animal medicines
6. Necessity for review of veterinary advertising regulations
7. Conclusions
8. Acknowledgment

Animal Health Innovation Asia 2019

We had the 4th Animal Health Innovation Asia 2019 in Tokyo on November 6th and 7th by receiving more than 150 attendee.
We were very happy to support the event as Consulting Partner.
Dr. Yuki Ujimasa, DVM, MS chaired a panel discussion and give two presentations as President of AHRMS, Inc. and President of Vm3, Inc., respectively.

Animal Health Innovation Asia 2019

Animal Health Innovation Asia 2019 will be held on November 6th and 7th at Hotel Westin Tokyo.
We, AHRMS, Inc., are supporting the event as “Consulting Partner” to fix the program, introduce Japanese start-ups and new technologies to multi-national animal health manufacturers and facilitate those companies to enter Japanese animal health markets.

Zoetis leads Japanese approvals in 2018 and across 10-year scope

News by Mr. Joseph Harvey, Editor of Animal Pharm

Zoetis received three approvals from the Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF) in 2018, bolstering its position as the firm with the most new products in Japan over the last 10 years.

The JMAFF approved 14 new animal drugs in 2018. These products included five antimicrobials, four pharmaceuticals, three biologicals and two antiparasitics. There were eight approvals for livestock and six authorizations for companion animals. 

The number of JMAFF approvals is down by one in comparison to 2017’s total.

Regarding marketing approvals for new animal health products in Japan between 2009 and 2018, Tokyo-based animal health consultancy AHRMS said Zoetis had received the most.

The president of AHRMS – Yuki Ujimasa – told Animal Pharm: “The largest number of approvals was gained by Zoetis (37) followed by Kyoritsu Seiyaku (30), MSD Animal Health (18), Kyoto Biken (18), KM Biologics (17.5), Novartis Animal Health (11), Boehringer Ingelheim Animal Health (11), Merial (10), Nisseiken (9), Elanco (8), DS Pharma Animal Health (8), Zenoaq (6), Bayer Animal Health (5) and Meiji Seika Animal Health (5).”

Of these approvals, 100 were for international businesses and 93.5 for domestic companies.

Dr Ujimasa explained: “The number includes pharmaceuticals, biologicals and diagnostics for dogs, cats, cattle, swine, poultry and fish. Generics and claim extensions are excluded. Approvals for a new species is counted as ‘1’.  A product of co-registration with two companies is counted as ‘0.5’.” 

Seminar for vets in Tokyo

Dr. Yuki Ujimasa, DVM, MS delivered lecture presentations entitled “Current status of veterinary medicine and the distribution of unapproved and counterfeit drugs overseas and in Japan” at a regulatory seminar hosted by Tokyo Metropolitan Government in February and March.